Impact of COVID-19 on Rheumatic Diseases in India: Determinants of Mortality and Adverse Outcome: A Retrospective, Cross-Sectional Cohort Study

• DOI: 10.4103/injr.injr_278_21
• Publication Date: 2022-07-25T10:41:58Z
• Authors: Avinash Jain; Vineeta Shobha; Chandrashekara S; Padmanabha Shenoy; Sapan C Pandya; Prashant Chotalia; Sharath Kumar; Sourabh Malviya; Yogesh Preet Singh; Abhishek Patil; Vikas Gupta; Puja Srivastava; Vijaya Prasanna P...; Chanakya Kodishala; Ramya Janardana; Benzeeta Pinto; Sudhir Bhandari; Govind Rankawat; Praveen Pratap Ja...; Damodaram Potugari; Vishnu Sharma; Alpana Parmar; Sunitha Kayidhi; Paul T Antony; Ashish Badika; Amit Sharma
• Keywords: Cross-sectional study

Introduction: There is varying impact of COVID19 on world population depending ethnicity, age and underlying co-morbidities. However, the lack data regarding effect COVID patients with rheumatological disorders (RDs) from different nations adds to uncertainty disease outcome. Across world, many rheumatology associations have joined hands collate-related information. A national database under Indian Rheumatology Associations (IRAs) was developed understand RD immunosuppressants during pandemic its severity outcome in our country. Methods: All registered members IRA were invited participate this registry provide information reverse transcription–polymerase chain reaction confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)-infected using an online platform https://iradatabaseard.in/iracovid/index.php. The results analyzed appropriate statistics. Multivariate logistic regression used analyze variables mortality. Odds ratio 95% confidence interval define risk death. Results: In retrospective cross-sectional study, for 447 who infected SARS-CoV2 available as December 1, 2020. mean 47.9 ± 14.4 years, including two children 93 (20.8%) geriatric group patients, male: female 0.4:1 duration 79.3 77.1 months. Rheumatoid arthritis most common RD. Underlying quiescent 54.7% active 18.4% patients. Most medications at time diagnosis steroids (57.76%) hydroxychloroquine (67.34%). Fever cough symptoms. More than half (54.4%) needed hospitalization. Oxygen requirement noted 18.8%, intensive care unit admission, invasive ventilation 6.0%, 2.9% respectively. Complete recovery seen 95.5% 4.47% (n = 20) expired due COVID. presence comorbidity, dyspnea, a higher neutrophil count statistically significantly associated death (P < 0.05). None other factors affected COVID-19 Conclusion: This largest cohort single nation looking interface between indicate that do not show increased mortality despite current use disease-modifying anti-rheumatic drugs/immunosuppressants.